Q-omics provides the consensus-scored TXK profile across patient tissues and cancer cell-line models. TXK expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TXK is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, TXK RNA expression shows 19,127 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, LUAD, and UVM as cancer lineages where TXK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TXK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TXK survival associations across molecular data types. TXK RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TXK RNA expression–survival associations across cancer types. High TXK expression shows unfavorable associations in LGG, but favorable associations in HNSC, SKCM, KIRC, READ and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TXK RNA expression.
This table summarizes TXK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for TXK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TXK shows lower tumor expression in LUAD, LUSC, KIRP, BRCA, COAD and HNSC. The LUAD box plot shows higher TXK RNA expression in normal versus tumor tissue (log2 FC = −0.691, t-test p < 0.001).
This table shows molecular features associated with TXK in patient tissues and cancer cell lines. In patient samples, TXK shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TXK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
